Calderasib + Durvalumab for Lung Cancer

This trial tests a new treatment for non-small cell lung cancer (NSCLC) with a KRAS G12C gene mutation. The researchers aim to determine if adding calderasib (MK-1084) to durvalumab, an immunotherapy, can prevent the cancer from growing or spreading after chemotherapy and radiation. Participants will receive either calderasib with durvalumab or a placebo with durvalumab to compare effectiveness. Suitable candidates have NSCLC that hasn't spread after standard chemoradiotherapy and show the KRAS G12C mutation in their tumor. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to a potentially groundbreaking treatment.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that calderasib, when combined with treatments like pembrolizumab, proves very effective for patients with a specific lung cancer mutation. In some studies, up to 72% of patients responded positively. However, other research has identified serious side effects. Six patients experienced significant side effects, including one severe kidney injury and two deaths.

Durvalumab, another drug in this trial, has been studied previously and is already approved for certain cancers. Long-term studies have shown that about 43% of patients who took durvalumab were still alive five years later. While this suggests effectiveness, there remains a risk of side effects.

Researchers are excited about Calderasib combined with Durvalumab because this treatment offers a novel approach for tackling lung cancer. Unlike the standard therapies, such as chemotherapy and radiation, which broadly target cancer cells, Calderasib works by specifically inhibiting a protein involved in cancer cell growth, potentially leading to more precise and effective treatment. Additionally, when combined with Durvalumab, an immunotherapy drug that helps the immune system recognize and attack cancer cells, this combination could enhance the body's natural defenses against the disease. This dual approach not only aims to improve treatment effectiveness but also hopes to reduce side effects associated with more generalized cancer treatments.

Research has shown that calderasib, a drug targeting a specific mutation in lung cancer, yields promising results. When combined with pembrolizumab, calderasib helped up to 72% of patients with a certain type of advanced lung cancer respond to treatment. In this trial, participants will receive either the combination of calderasib and durvalumab or a placebo with durvalumab. Durvalumab, used after chemotherapy and radiation, has demonstrated significant benefits; specifically, 55.9% of patients treated with durvalumab were free from cancer progression after a year, compared to 35.3% who received a placebo. Researchers are now exploring the combination of calderasib and durvalumab to improve these outcomes, with calderasib specifically targeting the KRAS mutation found in some lung cancers.¹³⁶⁷⁸